Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Tango Therapeutics (TNGX) EBT Margin (2020 - 2025)

Tango Therapeutics has reported EBT Margin over the past 6 years, most recently at 29.5% for Q3 2025.

  • Quarterly results put EBT Margin at 29.5% for Q3 2025, up 28032.0% from a year ago — trailing twelve months through Dec 2025 was 162.85% (up 14639.0% YoY), and the annual figure for FY2025 was 162.85%, up 14639.0%.
  • EBT Margin for Q3 2025 was 29.5% at Tango Therapeutics, up from 1220.31% in the prior quarter.
  • Over the last five years, EBT Margin for TNGX hit a ceiling of 29.5% in Q3 2025 and a floor of 1220.31% in Q2 2025.
  • Median EBT Margin over the past 5 years was 419.8% (2022), compared with a mean of 412.22%.
  • Biggest five-year swings in EBT Margin: skyrocketed 28926bps in 2023 and later tumbled -109208bps in 2025.
  • Tango Therapeutics' EBT Margin stood at 382.59% in 2021, then dropped by -18bps to 452.49% in 2022, then fell by -25bps to 565.57% in 2023, then tumbled by -62bps to 913.8% in 2024, then skyrocketed by 103bps to 29.5% in 2025.
  • The last three reported values for EBT Margin were 29.5% (Q3 2025), 1220.31% (Q2 2025), and 738.91% (Q1 2025) per Business Quant data.